Clinical trials: Acute Rejection
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Heart Transplant, Acute Graft Rejection
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal…
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Trial name
- NCT02597543
- Testing
- Regadenoson, Gadolinium, Cardiac MRI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Paul Kim
Kidney Transplantation
Rituximab for Pediatric Renal Transplant Rejection
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
- Trial name
- NCT00697996
- Testing
- Rituximab for transplant rejection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Kidney Transplantation
Effect of BM-MSCs on Chronic AMR After Kidney Transplantation
This study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR) after kidney transplantation.
- Trial name
- NCT02563340
- Testing
- BM-MSCs, Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Heart Transplant Rejection
Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain.
- Trial name
- FreeDNA-CAR (NCT04973943)
- Testing
- Donor-derived cell Free DNA
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Puerta de Hierro University Hospital
Thoracic Organ Transplantation
Genome Transplant Dynamics
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early.
- Trial name
- NCT02423070
- Where
- 7 sites in United States
- Volunteers
- 991 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Cardiac Transplant Rejection
The "no Biopsy Approach" for Heart Transplantation Follow-up
Pathological analysis is the gold standard for diagnosis of acute allograft rejection after heart transplantation (HTx). This method requires repeated endomyocardial biopsies during the first post-operative year.
- Trial name
- NCT03959579
- Testing
- systematic endomyocardial biopsy.
- Where
- France
- Volunteers
- 269 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Transplant;Failure,Kidney, Transplant; Failure, Pancreas
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function…
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
- Trial name
- PancDX (NCT04166149)
- Testing
- dd-cfDNA Blood Test
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Maryland, Baltimore
Disorder Related to Renal Transplantation, Renal Transplant Rejection
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
This study evaluates the addition of "Kidney Solid Organ Rejection Test" (kSORT), in the clinical follow-up of renal transplant recipients, compared to clinical standard surveillance in the first two years after kidney…
- Conditions
- Disorder Related to Renal Transplantation, Renal Transplant Rejection, Acute Graft Rejection
- Trial name
- TITRATE (NCT02581436)
- Testing
- kSORT assay based follow-up, Standard follow-up
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Kidney de Novo Transplant
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.
All patients of the core study who are interested of being treated with EC-MPS will be included in an open-label extension study to collect further information on the long-term safety, tolerability and efficacy of this drug.
- Trial name
- NCT00238992
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Lung Transplant Rejection
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Lung transplantation is a consolidated treatment in selected patients with end-stage respiratory diseases; however, acute rejection remains an important cause of lung allograft loss and a risk factor for chronic allograft…
- Trial name
- NGS-ACRL (NCT05260372)
- Testing
- Quantification of donor-derived cell-free DNA
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cardiac Graft
Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging
Acute heart allograft rejection is a common complication after orthotopic heart transplantation. Primary objective of this study is to assess cardiac MRI as a tool for acute heart graft rejection screening, by detecting changes…
- Trial name
- DRAGON (NCT02400840)
- Testing
- cardiac MRI, gadobenic acid intravenous injection 0.2 ml/kg
- Where
- France
- Sponsor
- University Hospital, Rouen
Kidney Transplant, Kidney Transplantation
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
There is a need to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had kidney transplant.
- Trial name
- PROGENI-KI (NCT01289717)
- Where
- 5 sites in United States
- Volunteers
- 307 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Failure, Chronic
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive…
- Trial name
- NCT00275509
- Testing
- Thymoglobulin, Daclizumab, Plasmapheresis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University